Loading clinical trials...
Loading clinical trials...
A Prospective, Long-Term, Interventional, Active Extension Study to Evaluate the Safety and Tolerability of NBI-921352 as Adjunctive Therapy in Subjects With SCN8A Developmental and Epileptic Encephalopathy Syndrome (SCN8A-DEE)
Conditions
Interventions
NBI-921352
Locations
4
United States
UCSF Medical Center
San Francisco, California, United States
Children's National Hospital
Washington D.C., District of Columbia, United States
University of Rochester
Rochester, New York, United States
Cook Children's Medical Center
Fort Worth, Texas, United States
Start Date
July 12, 2022
Primary Completion Date
March 1, 2026
Completion Date
March 1, 2026
Last Updated
July 17, 2025
Lead Sponsor
Neurocrine Biosciences
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions